The unique position of stakeholders participating in the Medicines Transparency Alliance Zambia, means that the group are able to initiate discussions at many levels from grassroots to parliament. This is of great value in highlighting critical issues about the lack of access to essential medicines experienced by many citizens in Zambia and makes progress towards finding some solutions
This fact sheet gives a brief overview of the key facts regarding corruption in the pharmaceutical supply chain. It focuses on unethical practices in the medicines supply chain, factors contributing to pharmaceutical corruption, the impact of corruption, and the response of the WHO
The local manufacturing of pharmaceuticals is a hotly contested issue in many countries. It runs to the heart of key concerns such as quality, availability, and price of medicines. Some of the arguments of the local manufacturers are set out in this article by one of the co-chairs of the Medicines Transparency Alliance Uganda Council and Chairman of the Uganda Pharmaceutical Manufacturer's Association (UPMA)
This report focuses on three of 10 sub-Saharan countries that were covered by a study examining the quality of key antimalarial medicines. A total of 491 samples of anti-malarial medicines (both artemisinin-based combination therapy and sulfadoxine-pyrimethamine products) were collected from the public sector, the regulated private sector and the informal market in these three countries. The study revealed a high failure rate among sampled antimalarials in all three countries, based both on Minilab and full-compendial or quality control laboratory testing
This article looks at the ideas that Medicines Transparency Alliance (MeTA) is testing, in order to achieve its long term goal to make high-quality essential medicines available and affordable to poor people who are currently unable to access them; and at how these ideas are being put into practice in Ghana. Ghana is one of the seven countries involved in the pilot phase of MeTA, the other countries are Jordan, Kyrgyzstan, Peru, the Philippines, Uganda and Zambia
"This scoping study provides a quick assessment of the malaria treatment markets and the role played by patent medicine vendors in Nigeria, and offers ways to improve the regulation and provision of anti-malarial drugs. It documented the sources of drugs in the three states and people’s problems in getting access to appropriate treatment for malaria"
This bulletin reports on the results of a study in which a range of antimalarial drugs were procured from private pharmacies, shops and kiosks within the urban and peri-urban areas of Lusaka, Zambia and tested to measure the active pharmaceutical ingredient content against internationally acceptable standards
This project aims to strengthen health systems for malaria management by improving the supply and quality of antimalarials and related supplies; and by improving the management and use of antimalarials
This is a detailed manual giving a step by step approach to undertaking pharmacovigilance of antiretroviral medicines
This is a summary of a study that gathered clinical evidence comparing generic and brand-name used in cardiovascular disease and assessed the the perspectives of editors on this issue
This leaflet describes how counterfeit medicines may endanger people's health because their quality is unpredictable. It also considers the challenges faced in combating counterfeit medicines and the role of the IMPACT coalition
This article describes research conducted on a range of antimalarial drugs, procured from private pharmacies in urban and peri-urban areas in the major cities of six African countries which were subjected to semi-quantitative thin-layer chromatography (TLC) and dissolution testing to measure active pharmaceutical ingredient content against internationally acceptable standards
"Low-cost high-quality drugs benefit society and helps provide pharmaceutical companies a competitive edge. This study presents the issues that must be considered to achieve these common objectives in Bangladesh and explores options that the Government and the local industry could pursue. "Previous efforts to improve the drug quality in Bangladesh focused, without much success, on stricter regulation of the public market. This paper addresses this issue from a more private sector approach. The existing quality and price of pharmaceuticals are analysed and alternative mechanisms are explored to improve the quality and cost competitiveness of Bangladesh’s pharmaceuticals domestically and internationally"
This leaflet describes the initiatives that research-based biopharmaceutical companies are working on to improve access to health care in developing countries, including the research and development of new drugs, diagnostics and vaccines for AIDS, tuberculosis and malaria; and working with others to improve health care systems and access to medicines
This report assesses the quality of antiretroviral medicines obtained at accredited public and private sector antiretroviral procurement and treatment sites in selected African countries. The aim is to help with the development of appropriate quality assurance strategies for antiretrovirals
This report is intended to assist organisations purchasing pharmaceutical products, vaccines or other health sector goods, or who are otherwise involved in the prequalification, purchasing, storage and distribution of such products. It addresses the general requirement for the quality assurance system that needs to be in place at all procurement agencies and sets out recommendations that these agencies should implement when evaluating product needs, assessing the products offered and the manufacturing and supply arrangements. It also describes principles of purchasing pharmaceutical products, how to receive and store them; good distribution practices; and monitoring and reassessment of products and contracted-out activities. This document was previously published as Annex 6 of the 40th Report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations (Technical report 937, 2006).
The long-term goal of these recommendations is the design and implementation of a uniform and harmonised system that will ensure procurement of pharmaceutical products of defined quality for supply to patients, based on a mutually recognised process of prequalification of products and manufacturers by means of product dossier evaluation and inspection of manufacturing sites. This document was previously published as Annex 6 of the WHO Technical Report Series No. 937, 2006
This case-based brief describes how the President’s Emergency Plan for AIDS Relief (the US PEPFAR initiative) and the related Supply Chain Management System (SCMS) Project are working to increase transparency and provide a secure, high-quality supply of HIV/AIDS drugs to developing countries in Africa and Asia. Drug supply is an essential component of health care systems, accounting for 10-30 percent of health care costs. Drugs can be expensive, and willingness to pay for drugs is high, creating the danger that employees will divert drugs for re-packaging and sale in the grey market, or for personal use
The pharmaceutical sector faces many challenges, of which corruption adds a potentially deadly element when patients cannot afford extortion payments for the drugs they need, or they are sold counterfeit medicines
This study addresses the question of whether access to medicines can be improved in sub-Saharan Africa by producing them locally. For this production to be sustainable, it must be both economically viable while meeting quality standards, and result in the improvement of access along one or more of the following dimensions: geographical accessibility, physical availability, affordability and acceptability
Source e-bulletin on Disability and Inclusion